Skip to content
Avatar
🔬
building cells
🔬
building cells

Achievements

Achievements

Block or Report

Block or report mekanistic

Block user

Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users.

You must be logged in to block users.

Report abuse

Contact GitHub support about this user’s behavior. Learn more about reporting abuse.

Report abuse
mekanistic/README.md

Mekanistic Therapeutics, LLC 🔬🔬

U-M Venture Accelerator, 1600 Huron Parkway Ann Arbor, MI 48109

P: 734-998-8327

info@mekanistictherapeutics.com

MTX-211, designed through iterative rounds of synthesis, is a novel small molecule that represents a first in class opportunity to selectively inhibit EGFR and PI3K family members. It exhibits favorable pharmaceutical properties and the requisite profile for lead compound advancement: molecular weight of 478, clogP 4.69, rule of 5 compliant, facile synthesis (3 steps from readily available starting materials), 78% oral bioavailability, metabolic stability >60 minute half-life in human and mouse microsomes, cmax 10-100x higher than cellular EC90, strong selectivity toward EGFR and PI3K family members, and pharmacodynamic modulation of EGFR and PI3K pathway signaling in vivo and single agent efficacy in clinically relevant KRAS and BRAF mutant patient-derived colorectal (CRC) xenograft models. By virtue of its dual inhibitory profile against both EGFR and PI3K, MTX-211 is effective against resistance mechanisms to MEK inhibitor monotherapy. This is evidenced by a 300 to 500% increase in life span seen in KRAS or BRAF mutant CRC PDX-bearing mice co-treated with MTX-211 and a MEK inhibitor compared to single agent control arms. Promising preclinical data provide critical proof of concept to validate a clinical development path for this agent that targets the KRASmt or BRAFmt colorectal cancer patient subpopulations. Chemical development of MTX-211 has been initiated to deliver cGMP quality active pharmaceutical ingredient needed for IND-enabing toxicology studies.

Popular repositories

  1. profile

    HTML

5 contributions in the last year

Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Mon Wed Fri

Contribution activity

August 2021

mekanistic has no activity yet for this period.

Seeing something unexpected? Take a look at the GitHub profile guide.